{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:00:41Z","timestamp":1787022041385,"version":"build-2736575974"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0213557","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T14:33:15Z","timestamp":1551969195000},"page":"e0213557","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":21,"title":["Prevalence and determinants of non-adherence to Imatinib in the first 3-months treatment among newly diagnosed Ethiopian\u2019s with chronic myeloid leukemia"],"prefix":"10.1371","volume":"14","author":[{"given":"Atalay","family":"Mulu Fentie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fishatsion","family":"Tadesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephrem","family":"Engidawork","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-2860","authenticated-orcid":true,"given":"Am","family":"Gebremedhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"issue":"5586","key":"ref1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1136\/bmj.1.5586.201","article-title":"Chronic Granulocytic Leukaemia: Comparison of Radiotherapy and Busulphan Therapy: Report of the Medical Research Council\u2019s Working Party for Therapeutic Trials in Leukaemia","volume":"1","author":"B Therapy","year":"1968","journal-title":"Br Med J"},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/PPO.0b013e318237e5b7","article-title":"Development of an effective therapy for chronic myelogenous leukemia","volume":"17","author":"DW Woessner","year":"2011","journal-title":"Cancer J"},{"key":"ref3","first-page":"935","article-title":"Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia","volume":"8","author":"MH Cohen","year":"2002","journal-title":"Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia Approval Summary for Imatinib Mesylate Capsules in the Treatment of Chronic Myelogenous Leukemia"},{"issue":"8","key":"ref4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00277-005-1039-z","article-title":"Chronic myeloid leukemia: A model for oncology","volume":"84","author":"R Hehlmann","year":"2005","journal-title":"Ann Hematol"},{"issue":"5486","key":"ref5","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase","volume":"289","author":"T Schindler","year":"2000","journal-title":"Science"},{"key":"ref6","unstructured":"National Comprehensive Cancer Network. Chronic Myeloid Leukemia. 2018; Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/link.springer.com\/10.1007\/978-3-319-33198-0\" xlink:type=\"simple\">http:\/\/link.springer.com\/10.1007\/978-3-319-33198-0<\/ext-link>"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1634\/theoncologist.9-3-259","article-title":"Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach","volume":"9","author":"RM Stone","year":"2004","journal-title":"Oncologist"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: Terminology and definitions","volume":"11","author":"JA Cramer","year":"2008","journal-title":"Value Heal"},{"issue":"22","key":"ref9","doi-asserted-by":"crossref","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","article-title":"Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study","volume":"113","author":"L Noens","year":"2009","journal-title":"Blood"},{"issue":"14","key":"ref10","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"D Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","article-title":"Predictive validity of a medication adherence measure in an outpatient setting","volume":"10","author":"DE Morisky","year":"2008","journal-title":"J Clin Hypertens"},{"issue":"6","key":"ref12","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clml.2016.02.040","article-title":"Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients with Chronic Myeloid Leukemia Receiving Imatinib","volume":"16","author":"R Unnikrishnan","year":"2016","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"key":"ref13","first-page":"95","article-title":"Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?","volume":"10","author":"NAI Al-Dewik","year":"2016","journal-title":"Is"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00277-011-1359-0","article-title":"Good adherence to imatinib therapy among patients with chronic myeloid leukemia-a single-center observational study","volume":"91","author":"S J\u00f6nsson","year":"2012","journal-title":"Ann Hematol"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/01.mlr.0000114908.90348.f9","article-title":"Variations in patients\u2019 adherence to medical recommendations: A quantitative review of 50 years of research","volume":"42","author":"MR DiMatteo","year":"2004","journal-title":"Med Care"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s11096-013-9867-8","article-title":"Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients","volume":"36","author":"LC Chen","year":"2014","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"2015013","DOI":"10.4084\/mjhid.2015.013","article-title":"Factors influencing adherence to Imatinib in Indian chronic myeloid leukemia patients: A Cross-Sectional Study","volume":"7","author":"J Kapoor","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/bmjopen-2016-015332","article-title":"Barriers and facilitators to medication adherence: A qualitative study with general practitioners","volume":"8","author":"K Kvarnstrom","year":"2018","journal-title":"BMJ Open"},{"key":"ref19","first-page":"1925","article-title":"Understanding and Challenges in Taking Tyrosine Kinase Inhibitors among Malaysian Chronic Myeloid Leukemia Patients: A Qualitative Study","volume":"18","author":"YM Lim","year":"2017","journal-title":"Asian Pacific J Cancer Prev"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00432-017-2372-z","article-title":"Factors influencing adherence in CML and ways to improvement: Results of a patient-driven survey of 2546 patients in 63 countries","volume":"143","author":"J Geissler","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2147\/PPA.S92125","article-title":"Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment","volume":"9","author":"M Kek\u00e4le","year":"2015","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"ref22","first-page":"1","article-title":"Drivers and barriers to medication adherence in patients with chronic myeloid leukaemia: a qualitative study","volume":"3","author":"Mourek Jindrich","year":"2017","journal-title":"J Hem Onco Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0213557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:43:30Z","timestamp":1663029810000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0213557"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0213557","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]}}}